US Draft Bill Highlights Perceived China Biotech Threat

WuXi Scrambles To Avoid TikTok Moment

A draft bill from the US House related to national security issues sent WuXi Biologics' shares tumbling over concerns around increased US scrutiny of Chinese firms, which a company clarification did little to dispel.  

WuXi Biologics scrambles to clarify as US scrutiny over China increases • Source: Shutterstock

The US House Select Committee on the Chinese Communist Party, led by Republican lawmaker Mike Gallagher, has proposed a draft bill, BIOSECURE, unveiled on 25 January and aimed at curbing the sharing of genetic information with China's largest genomics firm BGI and its subsidiaries.

BGI, formerly Beijing Genomic Institute, is a Shenzhen-based genomics research and commercial company.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia